Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss
AVCRF has more than doubled off its 52-week low of $0.013.
Summary
Avricore Health Inc. reported a substantial decline in revenue and a significant comprehensive loss for the nine months ended September 30, 2025, leading to a material uncertainty regarding its ability to continue as a going concern following the expiration of its agreement with a major customer.
Key Events · Legal and Risk Events · AVCRF
-
Going Concern Warning Issued
Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.
-
Significant Revenue Decline
Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.
-
Shift to Comprehensive Loss
The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.
-
Cash Flow Deterioration
Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.
Analysis · AVCRF · Life Sciences
The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVCRF was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.01 to $0.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.